Journal article
Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder
T Banaschewski, C Soutullo, M Lecendreux, M Johnson, A Zuddas, P Hodgkins, B Adeyi, L Squires, D Coghill
CNS Drugs | ADIS INT LTD | Published : 2013
Abstract
Background: Optimal management of attention deficit hyperactivity disorder (ADHD) aims not only to ameliorate patients' symptoms, but also to improve health-related quality of life (HRQL) and functioning. A pivotal, 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents in ten European countries demonstrated that the stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well-tolerated treatment for symptoms of ADHD. Objective: The aim of this study was to assess HRQL and functional impairment outcomes in this clinical trial, using the Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE:PRF) and the..
View full abstractGrants
Funding Acknowledgements
This study was supported by funding from Shire Pharmaceuticals. Shire develops and markets drugs to treat psychiatric disorders, including ADHD. T. Banaschewski, D. Coghill, M. Johnson, M. Lecendreux, C. Soutullo and A. Zuddas were principal investigators in this clinical study. P. Hodgkins and L. Squires contributed to the study design. B. Adeyi was responsible for the statistical analysis. All authors were involved in discussion and interpretation of the data, critically revised the article and approved the manuscript before submission. Drs E. Southam and M. Cottingham of Oxford PharmaGenesis (TM) Ltd were funded by Shire to provide writing support, including editorial assistance, collation of the authors' comments and editing of the manuscript for submission.